Skip to main content

Biorce

Category: AI in Healthcare

An AI-native platform designed to automate and optimize the entire clinical trial lifecycle, from protocol design and feasibility analysis to site selection and execution. Biorce was founded in 2024. The company is led by Pedro Coelho. Based in Barcelona, Spain (HQ); Austin, TX & New York, NY (US offices). Team size: 11-50. Total funding raised: $62.5M. Latest round: Series A. Key investors include ["DST Global Partners","Norrsken VC","YZR Capital","Mustard Seed Maze","Endeavor Catalyst","Nik Storonsky (CEO of Revolut)","Arthur Mensch (CEO of Mistral AI)"].

Founded
2024
Headquarters
Barcelona, Spain (HQ); Austin, TX & New York, NY (US offices)
Team size
11-50
Total funding
$62.5M

Value proposition

Reduces clinical trial setup and protocol development time from months to minutes while increasing data accuracy and reducing the high failure rates associated with manual trial design.

Products and solutions

["Aika: The core AI-native engine for clinical trial management","Automated Protocol Design: Generative AI tool for drafting clinical study protocols","AI Feasibility Analysis: Predictive modeling for trial success and patient recruitment","Site Selection & Enrollment Optimizer: Data-driven identification of high-performing clinical sites"]

Unique value

Biorce is built as an 'AI-native' company rather than a legacy CRO adding AI features; its platform, Aika, treats clinical data as a dynamic ecosystem to solve structural inefficiencies in drug development.

Target customer

Global pharmaceutical companies, emerging biotechnology firms, and Contract Research Organizations (CROs).

Industries served

["Healthcare","Biotechnology","Pharmaceuticals","Life Sciences"]

Technology advantage

Leverages proprietary generative AI models trained on vast clinical datasets to automate complex documentation and predictive analytics, backed by a leadership team with deep PharmD and clinical operations expertise.

How they differentiate

Biorce differentiates through its 'AI-native' architecture, specifically its Aika platform, which automates the entire clinical trial lifecycle—from protocol design to site selection—reducing setup times from months to minutes. Unlike legacy providers that add AI features to old systems, Biorce uses generative AI to treat clinical data as a dynamic ecosystem.

Main competitors

["Unlearn.AI","QuantHealth","Medidata (Dassault Systèmes)","Veeva Systems"]

Key partnerships

["DST Global Partners (Lead Investor)","Norrsken VC","Strategic R&D presence in the United States","Technical backing from industry leaders including Arthur Mensch (CEO of Mistral AI) and Nik Storonsky (CEO of Revolut)"]

Notable customers

["Global Pharmaceutical Companies","Emerging Biotechnology Firms","Contract Research Organizations (CROs)"]

Major milestones

["Launched Aika, a proprietary AI-native engine for clinical trial management in 2023","Raised $9M Seed round in February 2024 to develop core AI models","Secured $52.5M Series A in February 2025 to drive international expansion","Established strategic R&D presence in the United States","Opened US offices in New York and Austin, Texas at 515 Congress Ave (April 2026)","Won the 4YFN26 Award at Mobile World Congress (March 2026)"]

Growth metrics

Achieved the largest Series A in Iberian healthtech history; targeting a headcount of 250 employees by end of 2026; ended 2025 at ~200% above revenue target; employee count ~98 as of Mar 2026.

Market positioning

High-growth AI disruptor in the Clinical Research Organization (CRO) and Clinical Trial Management System (CTMS) space.

Geographic focus

Europe (Headquarters in Barcelona) and North America (Strategic R&D and commercial expansion).

Patents and IP

Proprietary AI architecture and trade secrets; no specific public patent filings disclosed as of February 2025.

About Pedro Coelho

Pedro Coelho has over 15 years of experience in the life sciences and consulting industries. Before founding Biorce, he was a Partner at a specialized life sciences consultancy where he focused on clinical trial optimization and commercial strategy. He holds a PharmD from the University of Lisbon and completed a postgraduate program at Harvard Medical School. His career is defined by identifying and solving structural inefficiencies in drug development through technology.

Official website: